Today, the Reproductive Freedom Alliance filed an amicus curiae brief with the Supreme Court in the case of Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine, arguing that, if the Court allows a recent Fifth Circuit decision to stand, it could undermine Governors’ ability to provide adequate healthcare services and would have far-reaching implications beyond reproductive healthcare.
Mifepristone is a safe, highly effective, and widely used medication prescribed for medication abortions and miscarriage management – used in well over half of all abortions. This medication is a critical component of the reproductive healthcare system in states where abortion remains legal. Any rollback on access to mifepristone would cause major disruptions to state healthcare systems, further strain providers, and pose serious health risks to millions of women. Ideological extremists shouldn’t be allowed to overrule medical experts and decades of scientific evidence by curtailing access to safe, effective medication.
Furthermore, this lawsuit threatens to upend the federal FDA review process – a time-tested gold standard for rigor and risk mitigation – that Governors rely on to protect the health and well-being of their constituents. If the Court allows this decision to stand, there will be severe consequences for patient access to a wide range of safe and effective medications.
The brief argues:
“…[Governors] rely on FDA determinations to meet the needs of those seeking healthcare in their states. Nothing about this framework contemplates litigants outside of Reproductive Freedom Alliance states who morally disapprove of a particular drug using out-of-state federal courts to invalidate FDA’s expert judgment…This strategy, if successful, would have an enormously disruptive impact on state governance and hamstring Governors’ ability to fulfill their mandate of protecting public health and safety in the reproductive healthcare context and beyond.”